PTC Therapeutics Priced, Nasdaq: PTCT
Biotech targeting rare forms of muscular dystrophy and cystic fibrosis.
Industry: Health Care
First Day Return: +9.9%
PTCT
Biotech targeting rare forms of muscular dystrophy and cystic fibrosis.
| IPO Data | |
|---|---|
| IPO Date | 06/19/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $126 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | South Plainfield, NJ, United States |
| Founded | 1998 |
| Employees at IPO | 127 |
| Website www.ptcbio.com | |
IPO News for PTC Therapeutics
PTC Therapeutics (PTCT) Performance
